Portfolio of BB Biotech AG as of December 31, 2013

Positive biotech sector momentum continues - transformational new products the key driver

BB Biotech proposes a tax-efficient cash distribution of CHF 7.00 per share

The Nasdaq Biotech Index advanced another 8.3% (in USD) in the fourth quarter, crowning 2013 as one of the best years ever for biotech stocks. Both the top holdings and the more recently established midcap positions in BB Biotech's portfolio performed well. The investment company's shares ended the year with a fourth quarter performance of 10.4% (in CHF) and an annual performance of 66% (in CHF) - 5 percentage points more than the benchmark index. These excellent gains are fundamentally sound and driven in part by new product launches such as Actelion's Opsumit for pulmonary arterial hypertension and Gilead's Sovaldi for hepatitis C. Keeping the payout policy established in 2013, the Board of Directors will propose a cash distribution of CHF 7.00 per share at the upcoming annual general meeting corresponding to a yield of 5%.

BB Biotech Medienmitteilung Q4...      55 kb
distributed by